- Home
- / SAB Biotherapeutics
SAB Biotherapeutics
Stock Price
$2.9
2024-10-29
Market Capitalization
$26.7 M
2024-10-29
Revenue
$1.3 M
FY, 2024
SAB Biotherapeutics Summary
Company Summary
- Overview
- SAb Biotherapeutics is a biopharmaceutical company developing antibody therapeutics. It offers the DiversitAb platform that allows creating immunoglobulins to treat health challenges such as seasonal influenza, Type 1 diabetes, and cancer.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- Sioux Falls, SD, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Christoph Bausch, EVP & Chief Operating Officer
Tom Luke, Chief Medical Officer
Christine Hamilton, Director
LocationsView all
3 locations detected
Sioux Falls, SD HQ
United States
2301 East 60th St N
Cambridge, MA
United States
245 First St #1836
Sioux Falls, SD
United States
2100 East 54th St N
SAB Biotherapeutics Financials
Summary Financials
- Net income (Q1, 2026)
- ($18.9M)
- Cash (Q1, 2026)
- $20.5M
- EBIT (Q1, 2026)
- ($20.0M)
- Enterprise value
- $12.2M